These findings reveal that BM‐EVs initiate prometastatic cascades in orthotopic HCC by transferring ALKBH5‐targeting miR‐3190 and miR‐3190 is serving as a promising therapeutic target for inhibiting the progression of HCC in patients with bone metastasis. Here, ALKBH5 is linked to hepatocellular carcinoma.